Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.
Chemoradiotherapy
IMRT
Nasopharyngeal
Toxicities
Tumor
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
14
06
2023
accepted:
07
01
2024
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
aheadofprint
Résumé
This study aimed to investigate the clinical benefit of adding concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) patients with an intermediate risk (stage II and T3N0M0). A multicenter phase II randomized trial was conducted in intermediate-risk NPC patients. Enrolled patients were previously untreated and aged ranged from 18 to 70 years without severe coexisting diseases. Patients were randomly assigned to receive IMRT alone or IMRT+concurrent chemotherapy (CC; three cycles of 80 mg/m From November 2015 to July 2019, 42 patients with stage II and T3N0M0 NPC were enrolled; 20 patients received IMRT alone while 22 patients received IMRT+CC. After a median of 58 months of follow-up, we estimated the 3‑year PFS rates as 90% (IMRT group) and 86.4% (IMRT+CC group; hazard ratio 1.387, 95% confidence interval 0.240-8.014; P = 0.719). The 3‑year PFS, OS, and cumulative DMFS and LRRFS showed no significant differences between the two groups (P > 0.05). However, the IMRT group displayed a lower incidence of nausea/vomiting, leucopenia, and dry mouth than the IMRT+CC group. Adding CC to IMRT provided no survival benefit but increased treatment-associated toxicities in patients with intermediate-risk NPC.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to investigate the clinical benefit of adding concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) patients with an intermediate risk (stage II and T3N0M0).
METHODS
METHODS
A multicenter phase II randomized trial was conducted in intermediate-risk NPC patients. Enrolled patients were previously untreated and aged ranged from 18 to 70 years without severe coexisting diseases. Patients were randomly assigned to receive IMRT alone or IMRT+concurrent chemotherapy (CC; three cycles of 80 mg/m
RESULTS
RESULTS
From November 2015 to July 2019, 42 patients with stage II and T3N0M0 NPC were enrolled; 20 patients received IMRT alone while 22 patients received IMRT+CC. After a median of 58 months of follow-up, we estimated the 3‑year PFS rates as 90% (IMRT group) and 86.4% (IMRT+CC group; hazard ratio 1.387, 95% confidence interval 0.240-8.014; P = 0.719). The 3‑year PFS, OS, and cumulative DMFS and LRRFS showed no significant differences between the two groups (P > 0.05). However, the IMRT group displayed a lower incidence of nausea/vomiting, leucopenia, and dry mouth than the IMRT+CC group.
CONCLUSION
CONCLUSIONS
Adding CC to IMRT provided no survival benefit but increased treatment-associated toxicities in patients with intermediate-risk NPC.
Identifiants
pubmed: 38324078
doi: 10.1007/s00066-024-02201-1
pii: 10.1007/s00066-024-02201-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : No. 82160479
Organisme : Natural Science Foundation Key Projects of Guangxi
ID : No. 2018GXNSFDA050021
Organisme : the Guangxi Medical and health key discipline construction project
Organisme : CSCO Youth Innovative Oncology Research Fund
ID : No. Y-Young2020-0520
Organisme : Chongzuo City Science and Technology Plan Project
ID : No. 2018012
Organisme : Scientific Research Program of the Health Commission of Guangxi Zhuang Autonomous Region
ID : Nos. Z20201200, Z20170816, Z20170207
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet 394:64. https://doi.org/10.1016/s0140-6736(19)30956-0
doi: 10.1016/s0140-6736(19)30956-0
pubmed: 31178151
Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong NGW, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S (2017) Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw239
doi: 10.1093/jnci/djw239
pubmed: 27927756
Carman J, Strojan P (2012) Nasopharyngeal carcinoma in Slovenia, 1990–2003 (results of treatment with conventional two-dimensional radiotherapy). Rep Pract Oncol Radiother 17:71–78. https://doi.org/10.1016/j.rpor.2012.01.002
doi: 10.1016/j.rpor.2012.01.002
pubmed: 24377003
pmcid: 3863176
Sarmiento MP, Mejia MB (2014) Preliminary assessment of nasopharyngeal carcinoma incidence in the Philippines: a second look at published data from four centers. Chin J Cancer 33:159–164. https://doi.org/10.5732/cjc.013.10010
doi: 10.5732/cjc.013.10010
pubmed: 23958058
pmcid: 3966143
Kanno M, Narita N, Fujimoto Y, Wakisaka N, Yoshizaki T, Kodaira T, Makita C, Sato Y, Yamazaki K, Wakaoka T, Shimode Y, Tsuji H, Kito R, Ishinaga H, Hosokawa S, Takakura H, Nishimura K, Matoba T, Fujieda S (2019) Third epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan from 2006 to 2015. Cancers. https://doi.org/10.3390/cancers11081180
doi: 10.3390/cancers11081180
pubmed: 31443218
pmcid: 6721521
Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y, Ma J (2017) Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw 15:913–919. https://doi.org/10.6004/jnccn.2017.0121
doi: 10.6004/jnccn.2017.0121
pubmed: 28687579
Yang XL, Wang Y, Liang SB, He SS, Chen DM, Chen HY, Lu LX, Chen Y (2018) Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. BMC Cancer 18:606. https://doi.org/10.1186/s12885-018-4419-1
doi: 10.1186/s12885-018-4419-1
pubmed: 29843648
pmcid: 5975550
Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536–539. https://doi.org/10.1093/jnci/dji084
doi: 10.1093/jnci/dji084
pubmed: 15812080
Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103:1761–1770. https://doi.org/10.1093/jnci/djr432
doi: 10.1093/jnci/djr432
pubmed: 22056739
Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Wen YF, Guo L, Mo HY, Chen MY, Sun Y, Ma J, Tang LQ, Mai HQ (2019) Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer 110:24–31. https://doi.org/10.1016/j.ejca.2018.10.020
doi: 10.1016/j.ejca.2018.10.020
pubmed: 30739837
Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12. https://doi.org/10.1016/s0360-3016(02)02724-4
doi: 10.1016/s0360-3016(02)02724-4
pubmed: 12007936
Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G (2006) Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64:374–381. https://doi.org/10.1016/j.ijrobp.2005.07.968
doi: 10.1016/j.ijrobp.2005.07.968
pubmed: 16213105
Cao C, Jiang F, Jin Q, Jin T, Huang S, Hu Q, Chen Y, Piao Y, Hua Y, Feng X, Chen X (2018) Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension. Oral Oncol 79:27–32. https://doi.org/10.1016/j.oraloncology.2018.02.004
doi: 10.1016/j.oraloncology.2018.02.004
pubmed: 29598947
Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB (2004) Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 58:682–687. https://doi.org/10.1016/s0360-3016(03)01508-6
doi: 10.1016/s0360-3016(03)01508-6
pubmed: 14967420
Chau RM, Teo PM, Choi PH, Cheung KY, Lee WY (2001) Three-dimensional dosimetric evaluation of a conventional radiotherapy technique for treatment of nasopharyngeal carcinoma. Radiother Oncol 58:143–153. https://doi.org/10.1016/s0167-8140(00)00336-4
doi: 10.1016/s0167-8140(00)00336-4
pubmed: 11166865
Jin YN, Tang QN, Yao JJ, Xu XW, He WZ, Wang L, You YF, Peng KW, Jiang C, Xia LP (2021) The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment epstein-barr virus DNA: retrospective analysis with a large institutional-based cohort. Transl Oncol 14:100990. https://doi.org/10.1016/j.tranon.2020.100990
doi: 10.1016/j.tranon.2020.100990
pubmed: 33338876
Liu DH, Zhou XY, Pan YG, Chen S, Ye ZH, Chen GD (2020) Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: a propensity score matching study. Cancer Med 9:1287–1297. https://doi.org/10.1002/cam4.2785
doi: 10.1002/cam4.2785
pubmed: 31859464
Xu T, Zhou X, Shen C, Hu C (2018) Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: based on hazard-rate and patterns of recurrence. Oral Oncol 76:61–67. https://doi.org/10.1016/j.oraloncology.2017.11.022
doi: 10.1016/j.oraloncology.2017.11.022
pubmed: 29290287
Ahmed Z, Kujtan L, Kennedy K, Wood V, Schomas D, Subramanian J (2019) The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: retrospective analysis of the national cancer database. Cancer Med 8:1500–1507. https://doi.org/10.1002/cam4.2033
doi: 10.1002/cam4.2033
pubmed: 30790468
pmcid: 6488125
Luo S, Zhao L, Wang J, Xu M, Li J, Zhou B, Xiao F, Long X, Shi M (2014) Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 36:841–847. https://doi.org/10.1002/hed.23386
doi: 10.1002/hed.23386
pubmed: 23720240
Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J (2012) The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 104:331–337. https://doi.org/10.1016/j.radonc.2011.10.009
doi: 10.1016/j.radonc.2011.10.009
pubmed: 22103978
Sun Y, Tang LL, Chen L, Li WF, Mao YP, Liu LZ, Lin AH, Li L, Ma J (2012) Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system. BMC Cancer 12:68. https://doi.org/10.1186/1471-2407-12-68
doi: 10.1186/1471-2407-12-68
pubmed: 22336097
pmcid: 3332280
Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O’Sullivan B, Pang ES, O SK, Au GK, Lau JT (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J Clin Oncol 23:6966–6975. https://doi.org/10.1200/jco.2004.00.7542
doi: 10.1200/jco.2004.00.7542
pubmed: 16192584
Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20:2038–2044. https://doi.org/10.1200/jco.2002.08.149
doi: 10.1200/jco.2002.08.149
pubmed: 11956263
Zhang AM, Fan Y, Wang XX, Xie QC, Sun JG, Chen ZT, Zhu B (2012) Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy. Radiother Oncol 104:279–285. https://doi.org/10.1016/j.radonc.2012.08.022
doi: 10.1016/j.radonc.2012.08.022
pubmed: 22981609
Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B, Shahi S, Rai R, Ali J, Jiang W (2020) Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol 15:66. https://doi.org/10.1186/s13014-020-01508-4
doi: 10.1186/s13014-020-01508-4
pubmed: 32178698
pmcid: 7074987
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346. https://doi.org/10.1016/0360-3016(95)00060-c
doi: 10.1016/0360-3016(95)00060-c
pubmed: 7713792
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317. https://doi.org/10.1200/jco.1998.16.4.1310
doi: 10.1200/jco.1998.16.4.1310
pubmed: 9552031
Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, Miao J, Cao C, Jin T, Zhang Y, Qu Y, Chen X, Liu Q, Zhang S, Zhang J, Luo J, Xiao J, Xu G, Gao L, Yi J (2020) Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol 10:1314. https://doi.org/10.3389/fonc.2020.01314
doi: 10.3389/fonc.2020.01314
pubmed: 32850414
pmcid: 7426506
Xu C, Zhang LH, Chen YP, Liu X, Zhou GQ, Lin AH, Sun Y, Ma J (2017) Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J Cancer 8:287–297. https://doi.org/10.7150/jca.17317
doi: 10.7150/jca.17317
pubmed: 28243333
pmcid: 5327378
Lan XW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY (2017) Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0‑1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther 10:3853–3860. https://doi.org/10.2147/ott.S133917
doi: 10.2147/ott.S133917
pubmed: 28814884
pmcid: 5546817
Rodríguez-Caballero A, Torres-Lagares D, Robles-García M, Pachón-Ibáñez J, González-Padilla D, Gutiérrez-Pérez JL (2012) Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg 41:225–238. https://doi.org/10.1016/j.ijom.2011.10.011
doi: 10.1016/j.ijom.2011.10.011
pubmed: 22071451
Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8:187–198. https://doi.org/10.1634/theoncologist.8-2-187
doi: 10.1634/theoncologist.8-2-187
pubmed: 12697943
Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ (2004) The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22:4604–4612. https://doi.org/10.1200/jco.2004.10.074
doi: 10.1200/jco.2004.10.074
pubmed: 15542811
Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56. https://doi.org/10.1016/j.ijrobp.2005.06.037
doi: 10.1016/j.ijrobp.2005.06.037
pubmed: 16377415
Campian JL, Sarai G, Ye X, Marur S, Grossman SA (2014) Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 36:1747–1753. https://doi.org/10.1002/hed.23535
doi: 10.1002/hed.23535
pubmed: 24174270
pmcid: 4081494
Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS (2004) Quantification of plasma epstein-barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461–2470. https://doi.org/10.1056/NEJMoa032260
doi: 10.1056/NEJMoa032260
pubmed: 15190138